CDK4/6 inhibitor dosing study for older adults with metastatic breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This study tests two targeted therapy drugs, palbociclib and ribociclib, combined with hormone therapy for people aged 60 or older with hormone receptor-positive, HER2-negative metastatic breast cancer. The goal is to see how well this treatment works and to gather information that may help improve dosing for older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer that is hormone receptor-positive (HR+) and HER2-negative, meaning it is fueled by hormones and not by HER2 protein.
- Your cancer has spread to other parts of the body (metastatic), and you have not previously taken a CDK4/6 inhibitor (like palbociclib or ribociclib) for metastatic disease.
- You are age 60 or older.
- You are about to start hormone therapy (such as letrozole, anastrozole, exemestane, or fulvestrant) combined with palbociclib or ribociclib for the first time in the metastatic setting.
- Your blood counts and liver/kidney function are within acceptable ranges, as determined by standard lab tests.
- If you are taking ribociclib, your heart test (ECG) shows a normal QT interval (QTc 480 ms or less).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing whether adjusting the dose of a targeted therapy (CDK 4/6 inhibitor) based on a geriatric assessment can be as effective and safer for people aged 70 and older with advanced hormone receptor-positive, HER2-negative breast cancer. It aims to find the best dose to balance benefits and side effects.
This study looks at a drug called palbociclib, which is a targeted therapy for a certain type of breast cancer. It aims to understand how often it causes low white blood cell counts (neutropenia) and how that affects treatment success. If you have metastatic HR+/HER2- breast cancer and haven't been treated for it yet, this trial may be a good fit.
This study looks at how well CDK4/6 inhibitors (a type of targeted therapy) work in real-world patients with HR+/HER2- advanced breast cancer. By collecting medical data from people treated at this hospital, doctors hope to learn more about the effectiveness and safety of these drugs in everyday practice.
This study looks at how well a type of targeted therapy (called CDK4/6 inhibitors) combined with hormone therapy works as the first treatment for advanced breast cancer that is hormone receptor-positive and HER2-negative. Researchers want to find patterns that could help predict which patients benefit most.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This study looks at how well older breast cancer patients (70 years and older) do when treated with a type of drug called a CDK4/6 inhibitor along with hormone therapy after surgery. The goal is to use simple health checks to help doctors decide if this treatment is right for you.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.